EUCTR2008-000766-23-DE进行中（未招募）不适用
Effects of QuetiapineXR in schizophrenic patients with cannabis abuseand/or cannabis induced psychosis -pilot study
Medical School Hannover, Department of Psychiatry, Socialpsychiatry and Psychotherapy0 个研究点开始时间: 2008年5月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Females and/or males aged 18 to 60 years.
- •2. Provision of written informed consent. In case of acute psychosis written informed consent has to be obtained from the legal representative of the patient, if applicable or from two independent physicians not involved in the study. When the patient recovers, the written informed consent has to be signed by the patient itself.
- •3. A diagnosis of schizophrenia (ICD10: F20.0, F20.1, F20.2, F20.4, F20.5) with associated cannabis abuse and/or psychotic disorders through cannabis (ICD 10: F12.5, F12.7).
- •4. A score of at least 15 on the positive scale of the PANSS.
- •5. Female patients of childbearing potential must be using a reliable method of contraception and have a negative blood human chorionic gonadotropin (HCG) test at enrolment.
- •6. Able to understand and comply with the requirements of the study. In case of acute psychosis only those patients are included that are expected to understand the requirements under healthy conditions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnancy or lactation.
- •2. Any ICD10 F-criteria not defined in the inclusion criteria.
- •3. Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to themselves or others.
- •4. Known intolerance or lack of response to quetiapine fumarate as judged by the investigator.
- •5. Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir.
- •6. Use of any of the following cytochrome P450 3A4 inducers in the 14 days preceding enrollment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John’s Wort, and glucocorticoids.
- •7. Patients who require treatment with one or more additional neuroleptics to quetiapine.
- •8. Administration of a depot antipsychotic injection within one dosing interval (for the depot) before randomisation.
- •9. Substance or alcohol dependence within 4 weeks prior to enrolment, at enrolment and during the study (except for cannabis, caffeine or nicotine dependence), as defined by DSM-IV criteria.
- •10. Medical conditions that would affect absorption, distribution, metabolism, or excretion of study treatment.
- •11. Unstable or inadequately treated medical illness (e.g. congestive heart failure, angina pectoris, hypertension) as judged by the investigator.
- •12. An absolute neutrophil count (ANC) of = 1.5 x 109 per liter.
- •13. Involvement in the planning and conduct of the study.
- •14. Previous enrolment or randomisation of treatment in the present study.
- •15. A patient with Diabetes Mellitus (DM) fulfilling one of the following criteria:
- •Unstable DM as defined as enrolment glycosylated haemoglobin (HbA1c) >8.5 %.
- •Admitted to hospital for treatment of DM or DM related illness in past 12 weeks.
- •Not under physicians care for DM.
- •Physicians responsible for patient´s DM care has not indicated that patient´s DM is controlled. Physician responsible for patient´s DM care has not approved patient´s participation in the study.
- •Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the 4 weeks prior to inclusion. For thiazolidinediones (glitazones) this period should be at least 8 weeks.
- •Taking insulin whose daily dose on one occasion in the past 4 weeks has been more than 10% above or below their mean dose in the preceding 4 weeks.
- •Note: If a diabetic patient meets one of these criteria, the patient is to be excluded even if the treating physician believes that the patient is stable and can participate in the study.
- •16. Previous treatment with study medication within the last 4 weeks prior to enrolment into this study.
- •17. Participation in another drug trial within 4 weeks prior enrolment into this study or current participation in another clinical trial.
研究者
相似试验
终止
3 期
Quetiapine XR in Schizophrenic PatientsSchizophreniaNCT01071135Hannover Medical School5
进行中（未招募）
不适用
Quetiapine induced neuroplasticity in schizophrenic patients: A combined TMS and VBM studyEUCTR2007-000545-35-DEMedical Institutions of the District Oberpfalz/Bayern (MedBO GmbH)
已完成
不适用
Does Quetiapine improve mood symptoms in schizophrenia patients?SchizophreniaJPRN-UMIN000013542Yatsushiro Kosei Hospital30
Unknown
3 期
Clinical Benefits of Seroquel XR in Anxiety DisorderSchizophreniaAnxietyNCT01672554Corporation de Recherche en Neuropsycho Pharmacologie de Quebec40
进行中（未招募）
不适用
The Effect of the Atypical Antipsychotic Quetiapine in the Treatment of Postpartum Depressive Disorders with or without Psychotic SymptomsPostpartum depressive disorders with or without psychotic symptomsEUCTR2006-006427-39-DEAstraZeneca GmbH